CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF ORAL DISEASES IN CHILDREN WITH SECONDARY IMMUNE DYSFUNCTION: AN INDIVIDUALIZED MINIMALLY INVASIVE DENTAL CARE FRAMEWORK

Authors

Keywords:

secondary immune dysfunction; children; oral manifestations; oral mucositis; dental caries; candidiasis; periodontal inflammation; minimally invasive dentistry; personalized care; interdisciplinary management.

Abstract

Children with acquired or treatment-related immune impairment are vulnerable to a heterogeneous spectrum of oral complications, including mucosal infection, chemotherapy-associated mucositis, gingival inflammation and dental caries. However, secondary immune dysfunction is an etiologically diverse clinical descriptor rather than a uniform diagnosis, and its direct contribution to dental disease must be separated from medication-related salivary changes, dietary exposures and access to care. This narrative evidence synthesis aimed to characterize clinically relevant oral–immune relationships and to develop an individualized, minimally invasive dental-care framework for paediatric practice. Professional guidance and peer-reviewed clinical studies and reviews published through 14 November 2026 were critically examined, with priority given to paediatric immunosuppression, oral supportive care, caries prevention and periodontal assessment. The synthesis identified the importance of medical-treatment phase, immune and haematological status, oral lesion activity, salivary symptoms and family-related risk factors when selecting dental interventions. A 2024 systematic review of long-term childhood cancer survivors summarized 17 observational studies including 983 survivors and 1,266 controls, while a 2026 cross-sectional investigation assessed 441 children receiving chemotherapy; these sources describe clinical burden but cannot validate the proposed care pathway. Four evidence-to-practice tables and a five-stage triage and monitoring framework are proposed. A prevention-first strategy combining coordinated medical clearance, conservative lesion management and continuous reassessment appears clinically plausible. Its safety, feasibility and effectiveness require prospective validation in clearly defined secondary-immunodeficiency subgroups.

References

1. American Academy of Pediatric Dentistry. Dental management of pediatric patients receiving immunosuppressive therapy and/or head and neck radiation. The Reference Manual of Pediatric Dentistry. 2026–2027:600–610. https://www.aapd.org/research/oral-health-policies--recommendations/dental-management-of-pediatric-patients-receiving-Immunosuppressive-therapy-andor-radiation-therapy/

2. American Academy of Pediatric Dentistry. Antibiotic prophylaxis for dental patients at risk for infection. The Reference Manual of Pediatric Dentistry. Revised 2026. https://www.aapd.org/research/oral-health-policies--recommendations/antibiotic-prophylaxis-for-dental-patients-at-risk-for-infection/

3. American Academy of Pediatric Dentistry. Caries-risk assessment and management for infants, children, and adolescents. The Reference Manual of Pediatric Dentistry. Revised 2022. https://www.aapd.org/research/oral-health-policies--recommendations/caries-risk-assessment-and-management-for-infants-children-and-adolescents/

4. American Academy of Pediatric Dentistry. Policy on minimally invasive dentistry. The Reference Manual of Pediatric Dentistry. Adopted 2023. https://www.aapd.org/research/oral-health-policies--recommendations/policy-on-minimally-invasive-dentistry/

5. American Academy of Pediatric Dentistry. Periodontal conditions in pediatric dental patients. The Reference Manual of Pediatric Dentistry. Revised 2024. https://www.aapd.org/research/oral-health-policies--recommendations/risk-assessment-and-management-of-periodontal-diseases-and-pathologies-in-pediatric-dental-patients/

6. American Academy of Pediatric Dentistry. Fluoride therapy. The Reference Manual of Pediatric Dentistry. Revised 2023. https://www.aapd.org/research/oral-health-policies--recommendations/fluoride-therapy/

7. Gingival and periodontal diseases and conditions in children and adolescents: consensus report. Eur Arch Paediatr Dent. 2026;27:637–670. doi:10.1007/s40368-025-01154-y.

8. Elad S, Cheng K-KF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423–4431. doi:10.1002/cncr.33100.

9. Braguês R, Marvão MF, Correia P, Silva RM. Oral mucositis management in children under cancer treatment: a systematic review. Cancers. 2024;16:1548. doi:10.3390/cancers16081548.

10. Nurhidayah I, Nurhaeni N, Allenidekania, Gayatri D, Mediani HS. The effect of oral care intervention in mucositis management among pediatric cancer patients: an updated systematic review. J Multidiscip Healthc. 2024;17:3497–3515. doi:10.2147/JMDH.S467455.

11. MASCC/ISOO Oral Care Study Group. Dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy: a clinical practice statement. Support Care Cancer. 2025;33:853. doi:10.1007/s00520-025-09845-4.

12. Torrecillas-Quiles L, Gómez-Ríos I, Jiménez-García I, et al. Oral and dental sequelae after oncological treatment in children: a systematic review. J Clin Med. 2025;14:5479. doi:10.3390/jcm14155479.

13. Seremidi K, Gizani S, Dahllöf G, et al. Dental management of long-term childhood cancer survivors: a systematic review. Eur Arch Paediatr Dent. 2024;25:611–636. doi:10.1007/s40368-024-00896-5.

14. Al-Sayed AM, El-Tawil SB, Madney Y, Yousry YM. Oral manifestations of pediatric cancer patients receiving chemotherapy and dental awareness among their parents: a cross-sectional study. BMC Oral Health. 2026;26:633. doi:10.1186/s12903-026-07983-7.

15. Dental abnormalities in pediatric patients receiving chemotherapy. J Clin Med. 2024;13:2877. doi:10.3390/jcm13102877.

16. Panel on Opportunistic Infections in Children with and Exposed to HIV. Candida infections: pediatric opportunistic infections. Updated December 22, 2025. ClinicalInfo HIV.gov. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/candida-infections (accessed 14 November 2026).

17. American Dental Association. Human Immunodeficiency Virus (HIV): oral manifestations and pediatric considerations. ADA Oral Health Topics. https://www.ada.org/resources/ada-library/oral-health-topics/hiv/ (accessed 14 November 2026).

18. Slayton RL, Urquhart O, Araujo MWB, et al. Evidence-based clinical practice guideline on nonrestorative treatments for carious lesions. J Am Dent Assoc. 2018;149:837–849.e19. doi:10.1016/j.adaj.2018.07.002.

Published

2026-11-10